Nosa Plugs (NOSA) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
21 Aug, 2026Executive summary
Net sales for Q2 2026 reached TSEK 8,843, an 81% increase year-over-year, with year-to-date sales up 87% to TSEK 17,034.
EBITDA improved to TSEK -271 in Q2 from TSEK -1,255 last year, with adjusted Q2 EBITDA at SEK 0.6 million (7% margin) excluding non-recurring costs.
Operating profit for Q2 was TSEK -1,921, impacted by amortization related to the Pharmacure acquisition.
Cash flow from operating activities improved significantly, at TSEK -177 for Q2 versus TSEK -3,204 last year.
Major launches and distribution agreements expanded presence in France, Norway, Benelux, and the Middle East.
Financial highlights
Q2 gross margin was 64% (down from 71% last year); YTD gross margin also 64%.
Earnings per share for Q2 was SEK 0.00 (last year: -0.01); YTD EPS was SEK -0.01 (last year: -0.02).
Cash and cash equivalents at period end were TSEK 16,091, down from TSEK 33,638 a year ago.
Equity ratio at 61% at quarter end (last year: 92%).
Outlook and guidance
Strong order book entering Q3, with key milestones expected in the coming quarter.
Continued focus on efficiency improvements and cost-saving measures to enhance operating results.
Winter season expected to drive further sales growth.
Latest events from Nosa Plugs
- Net sales surged 94% year-over-year, with margin gains and expanded European distribution.NOSA
Q1 2026 - Q4 sales doubled and EBITDA turned positive, with strong growth from new markets and acquisitions.NOSA
Q4 2025 - Q3 sales fell 16% but YTD growth, improved margins, and the Nozoil acquisition support future gains.NOSA
Q3 2025 - Q2 saw 17% sales growth, improved margins, and a major acquisition, supporting 2025 profitability goals.NOSA
Q2 2025 - Acquisition of Pharmacure for 27.2 MSEK boosts growth and market reach in nasal health.NOSA
Investor Update - 124% sales growth and improved margins drive Nosa Plugs toward positive cash flow.NOSA
Q3 2024 - Record sales and margin, major new orders, and strong expansion in Q2 2024.NOSA
Q2 2024 - Aims for profitability by Q4 2025 and leadership in nasal health via growth and acquisitions.NOSA
CMD 2025 - 50% sales growth and first positive cash flow mark a strong Q1 for NOSA.NOSA
Q1 2025